Your browser doesn't support javascript.
loading
The evolutionary landscape of SARS-CoV-2 variant B.1.1.519 and its clinical impact in Mexico City
Alberto Cedro-Tanda; Laura Gomez-Romero; Nicolas Alcaraz; Guillermo de Anda-Jauregui; Fernando Penaloza; Bernardo Moreno; Marco A Escobar-Arrazola; Oscar A Ramirez-Vega; Paulina Munguia-Garza; Francisco Garcia-Cardenas; Mireya Cisneros-Villanueva; Jose L Moreno-Camacho; Jorge Rodriguez-Gallegos; Marco A Luna-Ruiz Esparza; Miguel A Fernandez-Rojas; Alfredo Mendoza-Vargas; Juan P Reyes-Grajeda; Abraham Campos-Romero; Ofelia Angulo; Rosaura Ruiz; Claudia Sheinbaum-Pardo; Jose Sifuentes-Osornio; David Kershenobich; Alfredo Hidalgo-Miranda; Luis A Herrera.
Afiliação
  • Alberto Cedro-Tanda; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Laura Gomez-Romero; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Nicolas Alcaraz; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Guillermo de Anda-Jauregui; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Fernando Penaloza; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Bernardo Moreno; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Marco A Escobar-Arrazola; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Oscar A Ramirez-Vega; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Paulina Munguia-Garza; Unidad de Investigacion Biomedica en Cancer, Instituto Nacional de Cancerologia-Instituto de Investigaciones Biomedicas, UNAM, Av. San Fernando 22, Belisario Do
  • Francisco Garcia-Cardenas; Instituto Nacional de Medicina Genomica, INMEGEN, Periferico Sur 4809, Arenal Tepepan, Tlalpan, 14610, Mexico City, Mexico
  • Mireya Cisneros-Villanueva; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Jose L Moreno-Camacho; Clinical Laboratory Division, Salud Digna, Culiacan, 80000, Sinaloa, Mexico
  • Jorge Rodriguez-Gallegos; Clinical Laboratory Division, Salud Digna, Culiacan, 80000, Sinaloa, Mexico
  • Marco A Luna-Ruiz Esparza; Innovation and Research Department, Salud Digna, Culiacan, 80000, Sinaloa, Mexico
  • Miguel A Fernandez-Rojas; Innovation and Research Department, Salud Digna, Culiacan, 80000, Sinaloa, Mexico
  • Alfredo Mendoza-Vargas; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Juan P Reyes-Grajeda; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Abraham Campos-Romero; Innovation and Research Department, Salud Digna, Culiacan, 80000, Sinaloa, Mexico
  • Ofelia Angulo; Secretaria de Educacion, Ciencia, Tecnologia e Innovacion, Mexico City, Mexico
  • Rosaura Ruiz; Secretaria de Educacion, Ciencia, Tecnologia e Innovacion, Mexico City, Mexico
  • Claudia Sheinbaum-Pardo; Gobierno de la Ciudad de Mexico
  • Jose Sifuentes-Osornio; Instituto Nacional de Ciencias Medicas y Nutricion Salvadro Zubiran, Mexico City, Mexico
  • David Kershenobich; Instituto Nacional de Ciencias Medicas y Nutricion Salvadro Zubiran, Mexico City, Mexico
  • Alfredo Hidalgo-Miranda; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
  • Luis A Herrera; Instituto Nacional de Medicina Genomica, INMEGEN, Mexico City, Mexico
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21262911
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
The SARS-CoV-2 pandemic is one of the most concerning health problems around the globe. We report the emergence of SARS-CoV-2 variant B.1.1.519 in Mexico City. This variant represented up to 90% of sequenced cases in February 2021. It is characterized by three amino acid changes in the spike protein T478K, P681H, and T732A. We report the effective reproduction number of B.1.1.519 and present evidence of its geographical origin based on phylogenetic analysis. We also studied its evolution via haplotype analysis and identified the most recurrent haplotypes. Finally, we studied the clinical impact of B.1.1.519 patients infected with variant B.1.1.519 showed a highly significant adjusted odds ratio (aOR) increase of 1.85 over non-B.1.1.519 patients for developing a severe/critical outcome (P = 0.000296, 1.33-2.6 95% CI) and a 2.35-fold increase for hospitalization (P = 0.005, 1.32-4.34 95% CI). The continuous monitoring of this and other variants will be required to control the ongoing pandemic as it evolves.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Experimental_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Experimental_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...